What it is.
Translational Research Program grants fund new and innovative research that shows high promise of moving from laboratory discoveries to clinical application.
What it does.
TRP grants are designed to help reduce the time between laboratory findings and actual treatment. LLS’s TRP grants have helped numerous renowned researchers advance their life-saving research into clinical trials.
Madhav Dhodapkar, MBBS
"It is an honor to receive this grant. It will enable us to gain fundamental insights into how myeloma develops and explore new approaches to target it in the clinic."
Lucy Godley, M.D., Ph.D.
The University of Chicago
"Receiving this award from LLS is a tremendous honor. The award will support work aimed at understanding the mechanisms underlying the defective hematopoiesis seen in patients with germline mutations in RUNX1, ANKRD26, or ETV6. We hope that our work will lead to new strategies to improve platelet function and decrease risk for developing leukemias in these patients."
Ulrich Steidl, M.D., Ph.D.
Albert Einstein College of Medicine
"Funding through the Translational Research Program of the LLS is vital for our research. It is especially helpful in allowing us to pursue proof-of-concept studies on fundamentally novel, not-yet-established targets and pathways for anti-leukemia therapy. This is how we will identify new and more effective treatments for leukemia and related diseases, including at the level of disease-driving stem cells."
Charles Mullighan, MBBS, MSc, M.D.
St. Jude Children’s Research Hospital
"This award will help me pursue research by understanding how the genetic changes we have identified in erythroleukemia, a highly aggressive form of leukemia, influence the development of disease, and how promising targeted treatment approaches may be used to treat patients. The support of LLS is critical in supporting research for uncommon but clinically problematic forms of leukemia such as this."
Jianhua Yu, Ph.D.
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
"With this award, we are able to generate CAR-T cells to target a novel tumor antigen for the treatment of relapsed multiple myeloma. This award provides us an excellent opportunity to translate our previous preclinical studies into the clinic to benefit multiple myeloma patients and put our research work on the map of real translational studies. We believe this award will result in more exciting and novel discoveries as well."
Iannis Aifantis, Ph.D.
New York University School of Medicine
“This award will give us the ability to study the role of Cohesin, a protein complex frequently targeted by mutations in several human tumors including acute myeloid leukemia (AML). It will help us understand the role of Cohesin in the regulation of gene expression and also test specific chemical compounds that could preferentially target leukemia cells that carry Cohesin mutations. This award is a collaborative effort between my group and the group of Dr. Ross Levine at Memorial Sloan Kettering Cancer Center.”
FY17 Grant Recipients
Iannis Aifantis, Ph.D., New York University School of Medicine
Targeting the tumor-suppressive functions of the cohesin complex in acute myeloid leukemia (AML).
Charles Mullighan, MBBS, MSc, M.D., St. Jude Children's Research Hospital
Therapeutic targeting of acute erythroid leukemia.
Ulrich Steidl, M.D., Ph.D., Albert Einstein College of Medicine
Mechanisms of initiation and therapeutic targeting of PU.1 low-induced AML.
Randall Davis, M.D., University of Alabama at Birmingham
Targeting FCRL1 for Treatment in CLL.
Todd Fehniger, M.D., Ph.D., Washington University School of Medicine in St. Louis
Translating cytokine-induced NK cell memory as adoptive immunotherapy for leukemia patients.
David Scadden, M.D., Massachusetts General Hospital
Developing brequinar, an inhibitor of DHODH, as differentiation therapy in acute myeloid leukemia.
Yong-Mi Kim, M.D., Ph.D., M.P.H., Children's Hospital Los Angeles
Overcoming drug resistance in leukemia using a novel integrin alpha4 inhibitor, AVA-4746.
Y. Lynn Wang, M.D., Ph.D., FCAP, The University of Chicago
Overcoming ibrutinib resistance in CLL by dual SYK/JAK inhibition with a single agent cerdulatinib.
Timothy Hughes, M.D., FRACP, FRCPA, M.B.B.S, South Australian Health & Medical Research Institute
Developing a bioassay-based algorithm for selecting frontline therapy in chronic myeloid leukemia.
Guy Sauvageau, M.D., PH.D., F.R.C.P., IRIC - Institut de Recherche en Immunovirologie et en Cancerologie
Development of companion therapies for poor outcome HMGA2+ acute myeloid leukemia.
Dan Landau, M.D, Ph.D., Weill Cornell Medical College
Algorithmically-driven personalized combination therapy for chronic lymphocytic leukemia.
Lucy Godley, M.D., Ph.D., The University of Chicago
Modeling myeloid malignancies mediated by germline RUNX1, ETV6, and ANKRD26 mutations.
Teresa Palomero, Ph.D., Columbia University Medical Center
Bringing new angioimmunoblastic T-cell lymphoma therapies to the clinic.
Andrés Ferreri, M.D., IRCCS, Fondazione Centro San Raffaele
Improving R-CHOP efficacy by NGR-tumor necrosis factor in relapsed/refractory primary CNS lymphoma.
George Weiner, M.D., University of Iowa
Enhancing Lymphoma checkpoint blockade immunotherapy by local modification of the microenvironment.
James Rubenstein, M.D., Ph.D., University of California, San Francisco
Precision medicine in CNS lymphoma: Targeting NFkB activation pathways.
Ricardo Aguiar, M.D., Ph.D., University of Texas Health Science Center at San Antonio
Targeting the tumor cell and the microenvironment in DLBCL.
Francesco Bertoni, M.D., Foundation for the Research and Cure of Lymphoma in Ticino
Novel small molecule targets FLI1 in lymphoma and T-ALL.
Jianhua Yu, Ph.D., The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
CS1 chimeric antigen receptor (CAR) T cells for treatment of high-risk multiple myeloma.
Ralph Sanderson, Ph.D., University of Alabama at Birmingham
Optimizing small molecule inhibitors of heparanase for myeloma therapy.
Noopur Raje, M.D., Massachusetts General Hospital
A multi-peptide vaccine with lenalidomide and PD-L1 blockade for smoldering multiple myeloma.
Madhav Dhodapkar, MBBS., Yale University
Targeting antigenic substrates in monoclonal gammopathy.
Daniel Starczynowski, Ph.D., Cincinnati Children's Research Foundation
Rational design of dual IRAK1/4 inhibitors as a new therapy for MDS.
Michael Kharas, Ph.D., Memorial Sloan Kettering Cancer Center
Targeting epigenetic alterations in MDS stroma that drive disease progression.
Amittha Wickrema, Ph.D., The University of Chicago
Therapeutic targeting of anemia in MDS by modulation of DOCK4 pathway.
Ronald Hoffman, M.D., Icahn School of Medicine at Mount Sinai
Treatment strategies for MPN by targeting the tumor suppressor p53.
Maria Figueroa, M.D., University of Michigan
Epigenetic markers of sensitivity and resistance to hypomethylating agents.
Stem Cell Transplants
Emmanuel Katsanis, M.D., The University of Arizona
A phase I/II study of haploidentical BMT with post-transplant cyclophosphamide and/or bendamustine.
Marie Bleakley, M.D., Ph.D., Fred Hutchinson Cancer Research Center
Prevention of relapse after stem cell transplantation by minor H antigen T cell immunotherapy.